Analysis of the efficacy and adverse effects of nusinersen in the treatment of children with spinal muscular atrophy in China
Brain and Behavior · 2024
DOI: 10.1002/brb3.3630 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Brain and Behavior, 2024. Verfasst von Dan Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China. Hauptthemen laut MEDLINE: Oligonucleotides. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key R&D Plan of Shaanxi Province.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Objective
This study was based on a retrospective clinical observational cohort study of a two‐center application of nusinersen in China to evaluate the clinical efficacy and adverse effects of nusinersen in the treatment of SMA (spinal muscular atrophy) Types 1–3.
Methods
Clinical data from children with clinically and genetically confirmed 5qSMA from a double center in western China (the Second Affiliated Hospital of Xi'an Jiaotong University and the Second Hospital of West China of Sichuan University). All children were younger than 18 years of age. Patients were assessed for motor function and underwent blood and fluid tests before each nusinersen injection.
Results
At 14‐month follow‐up, 100% of children had improved their HFMSE (Hammersmith Functional Motor Scale Expanded) score, 83.6% had improved their CHOP INTEND (Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders) score, and 66.6% had improved their RULM (Revised Upper Limb Module) score by ≥3 points from baseline, and their 6MWT (6‐min walk test) was 216.00 ± 52.08 m longer than at baseline. The age of the child at the start of treatment was negatively correlated with the clinical efficacy of nusinersen; the younger the child, the better the response to treatment. No significant adverse effects affecting the treatment and quality of life of the child were observed during the treatment of SMA with nusinersen.
Conclusion
This study concluded that nusinersen is clinically beneficial for children with SMA in western China, with mild adverse effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
- Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China.
ORCID-Profile: Shaoping Huang
Förderung
- Key R&D Plan of Shaanxi Province
Zitieren
APA
Li, D., Yang, J., Wang, X., Yang, L., Luo, R., & Huang, S. (2024). Analysis of the efficacy and adverse effects of nusinersen in the treatment of children with spinal muscular atrophy in China. Brain and Behavior. https://doi.org/10.1002/brb3.3630
Vancouver
Li D, Yang J, Wang X, Yang L, Luo R, Huang S. Analysis of the efficacy and adverse effects of nusinersen in the treatment of children with spinal muscular atrophy in China. Brain and Behavior. 2024. doi:10.1002/brb3.3630
BibTeX
@article{Li2024,
author = {Li, Dan and Yang, Jie and Wang, Xueying and Yang, Lin and Luo, Rong and Huang, Shaoping},
title = {Analysis of the efficacy and adverse effects of nusinersen in the treatment of children with spinal muscular atrophy in China},
journal = {Brain and Behavior},
year = {2024},
doi = {10.1002/brb3.3630}
}
EUVIMED